First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients’ selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to person-alize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review’s aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).

Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression / A. Prelaj, C.C. Pircher, G. Massa, V. Martelli, G. Corrao, G.L. Russo, C. Proto, R. Ferrara, G. Galli, A. De Toma, C. Genova, B.A. Jereczek-Fossa, F. de Braud, M.C. Garassino, S.E. Rebuzzi. - In: CANCERS. - ISSN 2072-6694. - 13:6(2021 Mar 15), pp. 1300.1-1300.22. [10.3390/cancers13061300]

Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression

C.C. Pircher
Secondo
;
B.A. Jereczek-Fossa;F. de Braud;
2021

Abstract

First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients’ selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to person-alize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review’s aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).
Immune checkpoint inhibitor; Immunotherapy; Local therapy; Non-small cell lung cancer; Oligoprogression; Resistance
Settore MED/36 - Diagnostica per Immagini e Radioterapia
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
cancers-13-01300-v3.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 722.43 kB
Formato Adobe PDF
722.43 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/826941
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact